

## **Robin Toft to Join Board of Innovative Biosensors, Inc.**

*College Park, MD, January 9, 2006 – Innovative Biosensors, Inc. (IBI), a company developing rapid, ultra-sensitive tests to detect harmful pathogens, today announced that Robin Toft, formerly of Roche Molecular Systems, Inc., will join its Board of Directors.*

Robin Toft has over 15 years of senior level sales and marketing experience in diagnostics, biotechnology, and life sciences companies. As Senior Vice President of Commercial Operations at Roche Molecular Systems, Robin led the global commercialization efforts for Roche's \$1.1 billion molecular diagnostic business. She also served as a member of the Roche Molecular Diagnostics Executive Operating Committee. Previously, she was Vice President of Sales and Marketing at an emerging San Francisco Bay area biotech company, ViroLogic, Inc. (now known as Monogram Biosciences), where she shared responsibility for commercial operations and strategic decisions. At Laboratory Corporation of America, Robin was head of marketing, sales, and business development for the company's national molecular diagnostics center, the Center for Molecular Biology and Pathology, headquartered in Research Triangle Park, North Carolina.

"I am honored to become a member of IBI's distinguished Board of Directors," said Toft. "I look forward to contributing to the company's future successes as they expand into the realm of clinical diagnostics."

"Robin brings a wealth of commercialization experience to our Board," said Joe Hernandez, IBI's President and CEO. "Her successful commercial operations management experience within several high caliber companies will offer IBI a valuable strategic perspective."

### **About Innovative Biosensors, Inc.**

Innovative Biosensors, Inc. is a privately held company developing novel technologies for the rapid detection of pathogens. The company's technology is expected to have broad applications in food testing, animal health, and human health care, including drug discovery and development and disease diagnosis. Additional information is available at [www.innovativebiosensors.com](http://www.innovativebiosensors.com)

*This release may contain forward-looking statements that are subject to certain risks and uncertainties, including Innovative Biosensors' mission to develop and commercialize instrument systems, Innovative Biosensors' ability to develop new technologies to conduct rapid diagnosis. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Innovative Biosensors cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: Innovative Biosensors' expectations that they will incur operating losses in the near future, the early stage of development of Innovative Biosensors' products and technologies, uncertainties related to preclinical and clinical testing and trials, uncertainties surrounding the availability of additional funding, Innovative Biosensors' reliance on research collaborations, the actions of competitors and the development of competing technologies, potential patent infringement claims against Innovative Biosensors' products, processes and technologies, Innovative Biosensors' ability to protect their patents and proprietary rights and uncertainties relating to commercialization rights.*

**Contact:**

Innovative Biosensors, Inc.

Media Relations

Phone: (301) 738-0604

[info@innovativebiosensors.com](mailto:info@innovativebiosensors.com)